[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335510-105":59,"doc-detail-335510-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","repid-as-a-potential-biomarker-and-therapeutic-target-for-lung-neuroendocrine-tumor","RepID as a potential biomarker and therapeutic target for lung neuroendocrine tumor","","Research on neuroendocrine tumors (NET), particularly small cell lung cancer (SCLC), highlights the need for biomarkers that better match diagnostic and therapeutic needs. The study evaluates RepID, a substrate receptor within the CRL4 ubiquitin ligase complex, as a candidate biomarker and therapeutic target. Analyses of CCLE/CellMinerCDB show high correlation between RepID transcripts and NE signature genes, while RepID protein is strongly expressed in SCLC tissues and selected cell lines. Functional viability testing after CRL-targeting drug treatment indicates RepID expression predicts drug sensitivity, supporting RepID as a novel NET and SCLC biomarker with potential for new therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repid-as-a-potential-biomarker-and-therapeutic-target-for-lung-neuroendocrine-tumor/335510/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repid-as-a-potential-biomarker-and-therapeutic-target-for-lung-neuroendocrine-tumor/335510.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are current NET biomarkers considered limited?","Question",{"text":112,"@type":113},"Existing biomarkers such as CHGA, INSM1, and SYP show diverse specificities and sensitivities, which constrains reliable diagnosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does RepID relate to CRL4 ubiquitin ligase complex biology?",{"text":117,"@type":113},"RepID is a DCAF-family substrate receptor that recruits CRL4 to chromatin, helping control replication origin licensing (rereplication) and mitotic exit via targeted ubiquitination.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence links RepID expression to NET and SCLC?",{"text":121,"@type":113},"CCLE/CellMinerCDB analysis shows a strong correlation between RepID transcript levels and NE signature gene mRNA expression, and RepID protein is highly expressed in SCLC patient tissues and some SCLC cell lines.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335510,1790192977,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRepID as a potential biomarker and therapeutic target for lung neuroendocrine tumor  \nJong-Uk Park1,2, Jae-Hyun Jo1,2, Sangjune Kim2, Christophe E. Redon3, Mirit I. Aladjem3, Yuri Seo4, Se Jin Jang4,5 & Sang-Min Jang1,2􀀍  \nNeuroendocrine tumor (NET) is a rare malignant tumor, notably small cell lung cancer (SCLC), a typeof lung neuroendocrine tumor, which has a survival rate of less than 7%. Although various biomarkers including CHGA (ChromograninA), INSM1 (Insulinoma-associated protein 1), and SYP (Synaptophysin) are extensively used for the diagnostic testing of NET, their diverse specificities and sensitivities are acknowledged as limitations. Here, we demonstrate that RepID (Replication initiation determinant protein), a component ofCRL4 (Cullin-RING ubiquitin E3 ligase 4), holds promise as a biomarker for identifying NET and SCLC. Analysis of the Cancer Cell Line Encyclopedia (CCLE) via the CellMinerCDB portal reveals a high correlation between RepID transcript levels and mRNA expression of NE signature genes. Additionally, RepID protein is highly expressed in SCLC patient tissues and a subset ofSCLC cell lines. Viability analysis following treatment with pevonedistat and SZL-P1-41 in SCLC cell lines and human SCLC-organoid models indicates that RepID expression determines the sensitivity to CRL-targeting anti-cancer drugs. These findings suggest that RepID represents a novel biomarker for NET and SCLC, and insights from RepID research in these cancers could lead to innovative therapeutic strategies.  \nKeywords Neuroendocrine tumor, Small cell lung cancer, RepID, CRL  \nNeuroendocrine tumor (NET) accounts for approximately 2% of all malignant tumors diagnosed in the western world and is classified as a rare tumor type1,2. NETs can originate from NE cells throughout the body, includingthe gastrointestinal tract, lungs, appendix, and pancreas1–5. Among these organs, 22–27% of NETs originate from the lungs, making it the second most frequent primary site3. In the three major types of lung cancer, approximately 80–85% of small cell lung cancers (SCLC) exhibit NE characteristics, whereas most non-small cell lung cancers (NSCLC) and other cancers do not show NE signatures4,5.  \nSCLC is one of the most lethal tumors, with fewer than 7% of diagnosed patients surviving up to 5 years3,6. The poor prognosis of SCLC is attributed to its aggressive characteristics, which include rapid proliferation, extensive metastasis, and high recurrence rates. SCLC is categorized into the following subtypes: (1) ASCL1 (Achaete-scute homolog 1),(2) NeuroD1 (Neurogenic differentiation 1),(3) POU2F3 (POU class 2 homeobox 3), and (4) YAP1 (Yes-associated protein 1)7,8. SCLC-A (ASCL1) and SCLC-N (NeuroD1) exhibit high levels of NE markers as neuroendocrine subtypes, whereas SCLC-P (POU2F3) and SCLC-Y (YAP1) are characterized as non-neuroendocrine subtypes and show low levels of NE markers8. Depending on the subtype, SCLC exhibits varied responses to representative NE markers such as chromogranin A (CHGA), synaptophysin (SYP), and insulinoma-associated protein 1 (INSM1) (1) . Consequently, the lack of specific biomarkers and the varied biomarker patterns continue to pose challenges in NET diagnosis. Additionally, the stagnation of therapies for SCLC, unchanged for approximately 30 years, alongside the development of resistance to chemo/radiotherapy, present significant limitations. The identification of novel biomarkers is imperative to address the diagnostic and therapeutic challenges in NET.  \nReplication initiation determinant protein (RepID/DCAF14/PHIP) belongs to the DDB1/CUL4-associated factor (DCAF) family, acting as a substrate receptor for the Cullin-RING ubiquitin ligase complex 4 (CRL4)9. RepID possesses various chromatin binding domains, including bromo and cryptic tudor domains9, 10, enabling it to strongly bind to chromatin and recruit the CRL4 complex to chroma","cbCaisuRdpGsJnZn","https://ap.wps.com/l/cbCaisuRdpGsJnZn","pdf",4682818,"English","# RepID as a Biomarker and Therapeutic Target\n## Limitations of Current NET Biomarkers\n## NET and SCLC Background and Subtypes\n## RepID Biology and CRL4 Function\n## RepID Expression Patterns in NET and SCLC\n## Drug Sensitivity Linked to RepID Expression","[{\"question\":\"Why are current NET biomarkers considered limited?\",\"answer\":\"Existing biomarkers such as CHGA, INSM1, and SYP show diverse specificities and sensitivities, which constrains reliable diagnosis.\"},{\"question\":\"How does RepID relate to CRL4 ubiquitin ligase complex biology?\",\"answer\":\"RepID is a DCAF-family substrate receptor that recruits CRL4 to chromatin, helping control replication origin licensing (rereplication) and mitotic exit via targeted ubiquitination.\"},{\"question\":\"What evidence links RepID expression to NET and SCLC?\",\"answer\":\"CCLE/CellMinerCDB analysis shows a strong correlation between RepID transcript levels and NE signature gene mRNA expression, and RepID protein is highly expressed in SCLC patient tissues and some SCLC cell lines.\"}]","RepID as a potential biomarker and therapeutic target for lung neuroendocrine tumor | PDF",1790011215,25]